This study aimed to evaluate the lipid-lowering effect of the MeOH extract of Aceriphyllum rossii and its CHCl 3 fraction, as well as its inhibitory activity on DGAT in vitro, in normal and hyperlipidemic mice. We separated the MeOH extract of A. rossii into two portions, a CHCl 3 -soluble part and the remaining water residue, and performed DGAT enzymatic activity assay on them. Further assessment carried out to reveal that the MeOH extract and its CHCl 3 fraction suppress the intestinal TG absorption after an acute lipid challenge, and ameliorate hyperlipidemia as well as obesity-related parameters (body weight gain, serum lipid profiles, and several adipose tissue weights) in HFD-induced obese mice. First, the MeOH extract and its CHCl 3 fraction strongly inhibit DGAT1 and DGAT2 in vitro enzymatic activity. Second, the MeOH extract and the CHCl 3 fraction inhibit intestinal TG absorption after an acute lipid challenge in mice. Finally, the CHCl 3 fraction ameliorates various parameters of HFD-induced obesity mice, including body weight gain and serum levels of TG and glucose. Data obtained from the results obviously indicated that A. rossii prevents HFD-induced hyperlipidemia as well as obesity in mice possibly by inhibiting DGAT activity. We suggest that A. rossii MeOH extract and its CHCl 3 fraction would be a useful material for the therapy of hyperlipidemia.
Increased levels of lipids, mainly the triacylglycerol (TG) and cholesterol in the blood, is known to the major risk factor of congestive heart disease (CHD), hypertension and stroke [1] . Although HMG-CoA reductase inhibitors (i.e. statins) as well as the cholesterol absorption inhibitors (e.g. ezetimibe) have been widely recommended for the treatment of dyslipidemias, a few limitations and drawbacks like cost, intolerance and adverse effects, ineffective, or only partially effective in lowering of cholesterol levels and thus capable of reducing only up to 40% risk of CHD [2] . Therefore, new drugs with new mechanism needed to be developed. Recently, the high prevalence of hyperlipidemia has led to increased research in traditional herbal medicines that have negligible adverse effects, as alternative weight-loss therapies.
The use of functional food or dietary therapy for restoring the metabolic imbalance is attractive to the public. Aceriphyllum rossii Engler (Saxifragaceae), a perennial herb indigenous to Korea, grows in scant amounts of soil on damp rocks along the valley in the central northern area. The young leaves and stems have been used as a nutritious food in Korea [3] . Previous studies have reported that the isolated several triterpenes and flavonol glycosides from A. rossii have acyl-CoA:cholesterol acyltransferase inhibitory activity as well as anti-bacterial, anti-complementary, anti-cancer, anti-inflammatory and anti-oxidant activities [4] [5] [6] [7] [8] [9] . Moreover, we previously demonstrated that oleanane-type triterpenoids of A. rossii exert the inhibitory activity of TG biosynthesis by decreasing the diacylglycerol acyltransferase (DGAT) [10] . Despite the numerous studies of A. rossii have been reported, to the best of our (10, 30 , 100, and 300 μg/mL) in human recombinant DGAT1 (A) or DGAT2 (B) enzymes, as described in 'In vitro assay for DGAT activity' in the Materials and Methods section. The data are presented as the means of three independent experiments performed in duplicate.
knowledge, there has not been any investigation into the activities of a crude MeOH extract of A. rossii and their solvent partitioned fractions.
In the present study, we have separated the MeOH extract of A. rossii into two portions, a CHCl 3 -soluble part and the remaining water residue, and performed DGAT enzymatic activity assay on them. Further assessment revealed that the MeOH extract of A. rossii and its CHCl 3 fraction suppress the intestinal TG absorption after an acute lipid challenge, and ameliorate hyperlipidemia as well as obesity-related parameters in HFD-induced obese mice.
Because DGAT is an attractive pharmaceutical target with the potential for treatment of diseases associated with abnormal metabolism of TG, we selected DGAT enzyme as a filtering tool for finding new bioactive natural material. The crude MeOH extract (MeOH) showed considerable inhibition of both the hDGAT1 and hDGAT2 activity by confirming the in vitro enzymatic activity assay. The extract was separated into two portions; a CHCl 3 -soluble part and the other remaining water residue. The CHCl 3 fraction (CHCl 3 ) exhibited more potent inhibitory effects against both DGAT1 and DGAT2 than the water fraction (H 2 O), suggesting that putative bioactive molecules were transferred into the CHCl 3 phase ( Figure 1A and 1B).
Because inhibition of intestinal TG biosynthesis pathway can reduce lipid absorption, we performed a time course study after oral lipid emulsion challenge. C57BL/6J mice were fasted overnight and then administered vehicle (0.5% CMC), MeOH extract (250 or 500 mg/kg), CHCl 3 fraction (250 or 500 mg/kg) or DGAT1 inhibitor (T863, positive control) via oral gavages. Thirty minutes later, all the mice orally given a corn oil bolus (9 g/kg) and serum TG levels were measured with different time intervals from 0 to 6 h. Figure 2 indicated that the postprandial serum TG levels had an upward trend until 2 h after administration of the corn oil bolus. The group administered MeOH extract at 250 mg/kg was not showed significant reduction of postprandial TG level; however, the treatment of 500 mg/kg MeOH extract markedly decreased serum TG level as comparable to those of DGAT1 specific inhibitortreated. In the result of the CHCl 3 fraction on postprandial TG absorption, the CHCl 3 fraction at 250 or 500 mg/kg significantly reduced the serum TG level ( Figure 3 ). Compared with MeOH extract, the CHCl 3 fraction showed much higher efficacy compared to MeOH extract, suggesting that the CHCl 3 fraction has enriched the putative active compounds. These results are consistent with the results in Figure 1 . Thus, we suggest that the MeOH extract of A. rossii and its CHCl 3 fraction inhibit the absorption of TG after an acute lipid challenge considering the possibility of blocking TG resynthesis through the inhibition of DGAT activity.
As a result of the present data, we assumed that putative bioactive molecules of the MeOH extract were transferred into the CHCl 3 phase. To determine whether the CHCl 3 fraction shows lipidlowering activity, we experimented on HFD-induced mice model. The change in body weight is shown in Figure 4A . The body weights in the experiment starting point were significantly higher in obese mice groups fed HFD for 3 weeks compared to the normal chow diet group. Consuming an HFD for an additional 9 weeks caused a 17% significant increase in body weight compared to the initial weight. The HFD-induced obese mice fed the CHCl 3 fraction (300 mg/kg, administrated orally once a day for 9 weeks) showed 7.6% lower body weights compared with mice fed the HFD only.
To further investigate the beneficial effects of the CHCl 3 fraction on the obese model, we measured the weight of liver and fat tissues, and analyzed the blood profile. Long-term HFD feeding significantly increased the weight of the liver; however, administrating the CHCl 3 fraction into the HFD mice slightly, but not significantly reversed HFD-induced liver weight gain ( Figure  4B ). The serum levels of glucose, cholesterol (HDL, LDL and total), and TG were measured ( Figure 4C ). Long-term HFD feeding increased plasma glucose, HDL, LDL, total cholesterol, and TG levels as well as liver GOT and GPT levels, the indicator of damaged liver cells. The CHCl 3 fraction-administrated HFD group showed obviously decreased blood glucose and TG levels, and slightly reduced cholesterol levels. To test whether the CHCl 3 fraction reduces cellular lipid accumulation linking adipose tissue mass, the weight of epididymal WAT (Epi), retroperitoneal WAT (Retro), and subcutaneous WAT (Sub) were analyzed. As a result, Retro and Sub masses were significantly decreased in the CHCl 3 fraction-administrated HFD group, reflecting a reduction of total fat tissue mass. Collectively, the CHCl 3 fraction of A. rossii ameliorates negative HFD-induced parameters, especially serum level of TG and glucose, which are associated with causing metabolic diseases.
Abnormalities in lipid metabolism are very commonly observed in obese patients. Approximately 60-70% of obese patients are dyslipidemia [11] . In terms of therapeutics, drugs reducing intestinal lipid absorption are promising strategy for treatment of both obesity and hyperlipidemia.
DGAT catalyzes the final step in the synthesis of TG from diacylglycerol and fatty acyl-CoA. Intestinal DGATs (also known as the two isoforms DGAT1 and DGAT2) are important in the cellular and systemic responses to dietary fat. In the small intestinal lumen, dietary TG is hydrolyzed to free fatty acids and monoacylglycerol by pancreatic lipase; then, free fatty acids and monoacylglycerol are absorbed to enterocytes, where they are resynthesized into TGs and incorporated into the core of chylomicrons, and then secreted via the lymphatic system into circulation [12] . In this procedure, DGAT has a key role in resynthesis and absorption of TG in enterocytes [13, 14] . In mouse intestine, DGAT1 and DGAT2 can be seem to complementarily work together in processing dietary fat by the intestine. Intestinal DGAT1 and DGAT2 contribute to TG synthesis that is both storage and secretion [15] . The distribution of DGAT1 and DGAT2 was similar in the subjects with the highest amounts in the proximal intestine and the lowest amounts in the distal intestine [16] . In human intestine, however, DGAT1 is abundant and DGAT2 is thought to be present in much lower amounts [17, 18] although a thorough evaluation of DGAT2 expression in human enterocytes has not been elucidated.
Aceriphyllum rossii has lipid-lowering activity
Natural Product Communications Vol. 13 (4) 2018 473 In this study, we obviously demonstrated that the MeOH extract of A. rossii and its CHCl 3 fraction exhibits lipid-lowering actions in normal and hyperlipidemic mice. First, the MeOH extract of A. rossii and its CHCl 3 fraction strongly inhibit DGAT1 and DGAT2 in vitro enzymatic activity (Figure 1) . Second, the MeOH extract and the CHCl 3 fraction inhibit intestinal TG absorption after an acute lipid challenge in mice (Figures 2 and 3) . Finally, the CHCl 3 fraction ameliorates various parameters of HFD-induced obesity mice, including body weight gain and serum levels of TG and glucose ( Figure 4) . Collectively, we suggest that A. rossii extract and its CHCl 3 fraction would be a useful material for the therapy of hyperlipidemia. rossii (5 kg) were extracted by maceration with MeOH (60 L) two times for two weeks at room temperature. The MeOH solutions were filtered, and then evaporated at 40°C under reduced pressure to give a MeOH extract (730 g). The MeOH extract (150 g) was suspended in 1.5 L of water and then partitioned two times with equal volume of CHCl 3 to yield a CHCl 3 -soluble fraction (50 g) and a H 2 O-soluble fraction (100 g). A part of CHCl 3 -soluble layer was dissolved in DMSO (Sigma, St. Louis, MO, USA) to obtain a final concentration of 100 mg/mL, and was stored at −20°C until required. To use, the extract was further diluted to different concentrations with cell culture media (DMSO < 0.1%).
Human DGAT1 and DGAT2 expression in Sf-9 cells and membrane preparation: Human recombinant DGAT1 and DGAT2 (hDGAT1 and hDGAT2) were overexpressed in Sf-9 insect cells using the Bac-to-Bac Baculovirus Expression System (Invitrogen) according to the manufacturer's instructions. hDGAT1 (NCBI Reference Sequence: AF059202) and hDGAT2 (BC015234) cDNA clones are the gift from 21C Human Gene Bank, Genome Research Center, KRIBB, Korea. The insert DNA was transferred into pFastBac1 donor vector (Invitrogen) to obtain the recombinant baculovirus. Sf-9 cells infected with the resultant baculovirus at 10 MOI for 72 h were harvested in ice-cold PBS and homogenized using sonicator (Fisher Scientific) in sucrose solution (250 mM sucrose, 10 mM Tris, pH 7.4, 1 mM EDTA, and 1 mM DTT). The homogenates were centrifuged at 600 g for 15 min at 4°C to remove nuclei debris. The resulting supernatants were further centrifuged at 100,000 g for 1 h at 4°C to collect total membrane fractions. The resultant membrane-pellets were resuspended and the protein concentration was quantified using the Bradford protein assay method.
In vitro assay for DGAT activity: DGAT activity was measured according to the method of Coleman et al. [20] . DGAT activity was determined by measuring the formation of Oral lipid tolerance test (OLTT): C57BL/6J mice (7-week-old) were acquired from the Dae-Han BioLink (Eumsung, Korea). All animal experiments were conducted using protocols approved by Institutional Animal Care and Use Committee at Korea Research Institute of Bioscience and Biotechnology. The animals were maintained in a pathogen-free and temperature-controlled room (22 ± 3°C) on a 12 h light/dark cycle and supplied with food and water ad libitum. Mice (n=7/group) were fasted overnight and orally dosed with vehicle (0.5% CMC), CHCl 3 fraction (30, 100 and 300 mg/kg) or DGAT1 inhibitor [12] (10 mg/kg, positive control). Thirty minutes after dosing, a corn oil bolus (9 g/kg) was administered via gavage, followed by collection of blood samples at different time points (0, 1, 2, and 6 h) for measurement of serum TG levels. Blood samples were obtained from mice on the experimental plots via a retro-orbital sinus puncture using a heparinized capillary tube.
Experiment on HFD-induced obesity mice model: Five-week-old C57BL/6J (male) mice were purchased from Jung-Ang Lab animals Co. (Seoul, Korea). Mice (n=8/group) were preliminarily fed normal chow for 1 week and then diet-induced obese mice groups were exposed to a high-fat diet (Table 1 ., Rodent Diet with 60 kcal% Fat, research diet) ad libitum for 3 weeks. Diet-induced obese mice fed a high-fat diet or normal chow-fed mice were treated with vehicle (3% HPMC, hydroxypropyl-methylcellulose) or CHCl 3 fraction of A. rossii MeOH extract at a dose of 300 mg/kg (200 μL) administrated orally once a day for 9 weeks. Body weight and food intake were monitored once a week and on day 65, all animals were sacrificed to acquire blood and tissue samples.
Statistical analysis:
All data are presented as mean ± standard deviation (SD). Statistical analysis was performed using student's ttest with GraphPad Prism 6 software. A p-value of <0.05 was considered to be significant.
